Pacak K, Tella SH. Pheochromocytoma and Paraganglioma. In: Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext. South Dartmouth (MA): MDText.com, Inc.Copyright © 2000-2022; 2000.

Jimenez C. Libutti S. Landry C. et al.

AJCC cancer staging manual.

Springer, New York, NYBuffet A. Burnichon N. Favier J. et al.

An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma.

Best Pract Res Clin Endocrinol Metab. 34: 101416Lenders J.W. Duh Q.Y. Eisenhofer G. et al.

Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.

J Clin Endocrinol Metab. 99: 1915-1942Fishbein L. Leshchiner I. Walter V. et al.

Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma.

Cancer Cell. 31: 181-193Selak M.A. Armour S.M. MacKenzie E.D. et al.

Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase.

Cancer Cell. 7: 77-85Castro-Vega L.J. Buffet A. De Cubas A.A. et al.

Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas.

Hum Mol Genet. 23: 2440-2446Cascón A. Comino-Méndez I. Currás-Freixes M. et al.

Whole-Exome Sequencing Identifies MDH2 as a New Familial Paraganglioma Gene.

JNCI: J Natl Cancer Inst. 107Zhuang Z. Yang C. Lorenzo F. et al.

Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia.

N Engl J Med. 367: 922-930Qin Y. Yao L. King E.E. et al.

Germline mutations in TMEM127 confer susceptibility to pheochromocytoma.

Nat Genet. 42: 229-233Comino-Méndez I. Gracia-Aznárez F.J. Schiavi F. et al.

Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma.

Nat Genet. 43: 663-667Amar L. Bertherat J. Baudin E. et al.

Genetic testing in pheochromocytoma or functional paraganglioma.

J Clin Oncol. 23: 8812-8818Amar L. Baudin E. Burnichon N. et al.

Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas.

J Clin Endocrinol Metab. 92: 3822-3828Gimenez-Roqueplo A.P. Favier J. Rustin P. et al.

Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas.

Cancer Res. 63: 5615-5621Benn D.E. Robinson B.G. Clifton-Bligh R.J.

15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1-5.

Endocr Relat Cancer. 22: T91-T103Benn D.E. Gimenez-Roqueplo A.P. Reilly J.R. et al.

Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes.

J Clin Endocrinol Metab. 91: 827-836Neumann H.P. Pawlu C. Peczkowska M. et al.

Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.

Jama. 292: 943-951Schiavi F. Boedeker C.C. Bausch B. et al.

Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene.

Jama. 294: 2057-2063Kunst H.P. Rutten M.H. de Mönnink J.P. et al.

SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma.

Clin Cancer Res. 17: 247-254Brouwers F.M. Eisenhofer G. Tao J.J. et al.

High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing.

J Clin Endocrinol Metab. 91: 4505-4509Ricketts C.J. Forman J.R. Rattenberry E. et al.

Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD.

Hum Mutat. 31: 41-51Kopetschke R. Slisko M. Kilisli A. et al.

Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma.

Eur J Endocrinol. 161: 355-361Dwight T. Benn D.E. Clarkson A. et al.

Loss of SDHA expression identifies SDHA mutations in succinate dehydrogenase-deficient gastrointestinal stromal tumors.

Am J Surg Pathol. 37: 226-233Buffet A. Ben Aim L. Leboulleux S. et al.

Positive Impact of Genetic Test on the Management and Outcome of Patients With Paraganglioma and/or Pheochromocytoma.

The J Clin Endocrinol Metab. 104: 1109-1118Toledo R.A. Burnichon N. Cascon A. et al.

Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas.

Nat Rev Endocrinol. 13: 233-247Pipitprapat W. Pattanaprateep O. Iemwimangsa N. et al.

Cost-minimization analysis of sequential genetic testing versus targeted next-generation sequencing gene panels in patients with pheochromocytoma and paraganglioma.

Ann Med. 53: 1243-1255Papathomas T.G. Oudijk L. Persu A. et al.

SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T).

Mod Pathol. 28: 807-821van Nederveen F.H. Gaal J. Favier J. et al.

An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis.

Lancet Oncol. 10: 764-771Gill A.J. Benn D.E. Chou A. et al.

Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes.

Hum Pathol. 41: 805-814Janssen I. Blanchet E.M. Adams K. et al.

Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma.

Clin Cancer Res : official J Am Assoc Cancer Res. 21: 3888-3895Timmers H.J. Chen C.C. Carrasquillo J.A. et al.

Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.

J Natl Cancer Inst. 104: 700-708Timmers H.J. Kozupa A. Chen C.C. et al.

Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.

J Clin Oncol. 25: 2262-2269Bhatia K.S. Ismail M.M. Sahdev A. et al.

123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation.

Clin Endocrinol (Oxf). 69: 181-188Wiseman G.A. Pacak K. O'Dorisio M.S. et al.

Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial.

J Nucl Med. 50: 1448-1454Pryma D.A. Chin B.B. Noto R.B. et al.

Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma.

J Nucl Med. 60: 623-630Livingstone M. Duttchen K. Thompson J. et al.

Hemodynamic Stability During Pheochromocytoma Resection: Lessons Learned Over the Last Two Decades.

Ann Surg Oncol. 22: 4175-4180Buitenwerf E. Osinga T.E. Timmers H. et al.

Efficacy of alpha-Blockers on Hemodynamic Control during Pheochromocytoma Resection: A Randomized Controlled Trial.

J Clin Endocrinol Metab. 105Prys-Roberts C. Farndon J.R.

Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma.

World J Surg. 26: 1037-1042Kong H. Li N. Tian J. et al.

The use of doxazosin before adrenalectomy for pheochromocytoma: is the duration related to intraoperative hemodynamics and postoperative complications?.

Int Urol Nephrol. 52: 2079-2085Buisset C. Guerin C. Cungi P.J. et al.

Pheochromocytoma surgery without systematic preoperative pharmacological preparation: insights from a referral tertiary center experience.

Surg Endosc. 35: 728-735Groeben H. Walz M.K. Nottebaum B.J. et al.

International multicentre review of perioperative management and outcome for catecholamine-producing tumours.

Br J Surg. 107: e170-e178Sloand E.M. Thompson B.T.

Propranolol-induced pulmonary edema and shock in a patient with pheochromocytoma.

Arch Intern Med. 144: 173-174Brogden R.N. Heel R.C. Speight T.M. et al.

alpha-Methyl-p-tyrosine: a review of its pharmacology and clinical use.

Drugs. 21: 81-89Jimenez C. Rohren E. Habra M.A. et al.

Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma.

Curr Oncol Rep. 15: 356-371Strajina V. Dy B.M. Farley D.R. et al.

Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series.

Ann Surg Oncol. 24: 1546-1550Ayala-Ramirez M. Feng L. Johnson M.M. et al.

Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.

J Clin Endocrinol Metab. 96: 717-725Roman-Gonzalez A. Zhou S. Ayala-Ramirez M. et al.

Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma.

Ann Surg. 268: 172-178Goffredo P. Sosa J.A. Roman S.A.

Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades.

J Surg Oncol. 107: 659-664Goers T.A. Abdo M. Moley J.F. et al.

Outcomes of resection of extra-adrenal pheochromocytomas/paragangliomas in the laparoscopic era: a comparison with adrenal pheochromocytoma.

Surg Endosc. 27: 428-433Nockel P. El Lakis M. Gaitanidis A. et al.

Preoperative genetic testing in pheochromocytomas and paragangliomas influences the surgical approach and the extent of adrenal surgery.

Surgery. 163: 191-196Assadipour Y. Sadowski S.M. Alimchandani M. et al.

SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.

Surgery. 161: 230-239Abadin S.S. Ayala-Ramirez M. Jimenez C. et al.

Impact of surgical resection for subdiaphragmatic paragangliomas.

World J Surg. 38: 733-741Hu H. Huang B. Zhao J. et al.

En Bloc Resection with Major Blood Vessel Reconstruction for Locally Invasive Retroperitoneal Paragangliomas: A 15-Year Experience with Literature Review.

World J Surg. 41: 997-1004Yip L. Lee J.E. Shapiro S.E. et al.

Surgical management of hereditary pheochromocytoma.

J Am Coll Surg. 198 (): 525-534Grubbs E.G. Rich T.A. Ng C. et al.

Long-term outcomes of surgical treatment for hereditary pheochromocytoma.

J Am Coll Surg. 216: 280-289Castinetti F. Qi X.-P. Walz M.K. et al.

Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study.

The Lancet Oncol. 15: 648-655Neumann H.P.H. Tsoy U. Bancos I. et al.

Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy.

JAMA Netw Open. 2: e198898Amin M. Edge S. Greene F. et al.

AJCC cancer staging manual.

8th edition. Springer International Publishing: American Joint Commission on Cancer, Hamidi O. Young Jr., W.F. Iniguez-Ariza N.M. et al.

Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.

J Clin Endocrinol Metab. 102: 3296-3305Ellis R.J. Patel D. Prodanov T. et al.

Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted?.

J Am Coll Surg. 217: 489-496Castinetti F. Taieb D. Henry J.F. et al.

MANAGEMENT OF ENDOCRINE DISEASE: Outcome of adrenal sparing surgery in heritable pheochromocytoma.

Eur J Endocrinol. 174: R9-R18Lenders J.W. Duh Q.Y. Eisenhofer G. et al.

Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.

J Clin Endocrinol Metab. 99: 1915-1942Plouin P.F. Amar L. Dekkers O.M. et al.

European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma.

Eur J Endocrinol. 174: G1-G10